search
Back to results

Oral Manifestations of Systemic Sclerosis

Primary Purpose

Scleroderma, Systemic

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Cone Beam Computed Tomography (CBCT)
Sponsored by
University Hospital, Strasbourg, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Scleroderma, Systemic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Common inclusion criteria
  • Males and females ≥ 18 years (18th birthday completed)
  • Affiliation to a social security scheme
  • Signed informed consent form prior to inclusion in the study
  • More than 12 natural teeth suitable for evaluation

Inclusion criteria for systemic sclerosis patients

  • Systemic sclerosis Inclusion criteria for control
  • Subjet that underwent or must undergo an upper and a lower jaw bone Cone Beam Computed Tomography examination (impacted teeth assessment, implant treatment planning)

Exclusion Criteria:

Common exclusion criteria

  • Overt acute or chronic infection (HIV, viral hepatitis…) known at the time of the oral examination
  • Progressive neoplasia or neoplasia diagnosed within 2 years prior to the study
  • Ongoing antibiotic treatment or within 3 months before oral examination
  • Individuals at risk of infective endocarditis
  • Oral antiseptics within the week before oral examination (chlorhexidine mouthwashes…)
  • Periodontal specialized treatments, root scaling/root planning or periodontal surgical treatment within the year before oral examination
  • Ongoing medical treatment inducing a significant modification of the gingival state (anti-epileptic drugs…)
  • Smoking (≥ 10 cigarettes per day)
  • Pregnancy female subjects (positive urine pregnancy test)
  • Lactating female subjects
  • Impossibility to provide accurate informations (emergency situation, comprehension difficulties…)

Exclusion criteria for systemic sclerosis patients

  • Patient currently involved in an other clinical trial (drug) or in an exclusion period following participation in another clinical trial
  • Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…)
  • Progressive chronic illness other than systemic sclerosis (diabetes…)
  • Immunosuppressive therapy during the last month
  • Corticosteroid ≥10 mg/day during the last month
  • Hematopoietic stem cell transplant recipient
  • Another cause of skin sclerosis (radiotherapy on the oro-facial region…)

Exclusion criteria for control

  • Systemic chronic or evolutive illness at the time of the inclusion
  • Progressive pathology involving the maxilla or the mandible at the time of the inclusion (tumor…)
  • Ongoing treatment with corticsteroids or non-steroidal anti-inflammatory drugs

Sites / Locations

  • Service de parodontologie

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Measurement of the periodontal ligament space

Radiographic analysis of oro-facial manifestations

Arm Description

Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.

Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.

Outcomes

Primary Outcome Measures

Measurement of the periodontal ligament space width at mid-root level on Cone Beam Computed Tomography (CBCT) axial views

Secondary Outcome Measures

Radiographic analysis of oro-facial manifestations associated with systemic sclerosis using high-resolution volumetric Cone Beam Computed Tomography (CBCT) exploration

Full Information

First Posted
February 18, 2015
Last Updated
September 13, 2021
Sponsor
University Hospital, Strasbourg, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02371005
Brief Title
Oral Manifestations of Systemic Sclerosis
Official Title
Oral Manifestations of Systemic Sclerosis: Toward the Identification of New Prognostic Markers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Terminated
Why Stopped
scleroderma patients were difficult to recruit
Study Start Date
June 2015 (Actual)
Primary Completion Date
June 2021 (Actual)
Study Completion Date
June 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Strasbourg, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Systemic sclerosis (SSc) is a rare multisystem connective-tissue disorder characterized by three major pathological hallmarks: widespread fibrosis, vasculopathy and immunological abnormalities. As all connective tissues can be affected, this condition has multiple effects on the orofacial region. Indeed, the latter is involved in approximately 80% of SSc patients. Oral manifestations have a major impact on quality of life and require specific treatments that should be performed as early as possible. Widening of the periodontal ligament space, that seems to be linked to an increased collagen synthesis, is one of the most common dental radiographic finding. However, this radiologic sign has been mostly studied on two-dimensional radiographs. The investigators have recently described in a patient suffering from SSc the existence of calcifications within the periodontal ligament space using Cone Beam Computed Tomography (CBCT) approach (Jung et al., Oral Surg Oral Med Oral Pathol Oral Radiol 2013). Such calcifications, that have never been observed before, could be part of the phenotypic spectrum of the disease, in particular when dystrophic calcinosis is associated. They could furthermore constitute a specific feature of SSc. However, this radiographic sign requires to be investigated in a largest number of patients. Several cytokines have been implicated in SSc pathogenesis. A recent study has revealed that elevated CXCL4 serum levels correlate with disease complications, suggesting that this molecule could be used as a prognostic biomarker. Increased IL-6 serum levels also correlate with SSc severity. Gingival crevicular fluid can be easily collected from the gingival crevice surrounding the teeth and constitute an indicator of local but also systemic inflammation. Analysis of gingival crevicular fluid cytokine profile could contribute to the identification of specific SSc biomarkers and allow a better comprehension of oral manifestations pathogenesis. The aim of this case-control study is to characterize precisely the oral manifestations associated with SSc within the National Referral Center for Rare Autoimmune Diseases (Strasbourg, France) patient cohort in order to identify specific radiological, clinical and/or biological signs. Some of them could be correlated to the severity or to the prognosis of the disease. To the investigators knowledge it is the first study using tridimensional CBCT approach.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scleroderma, Systemic

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
85 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Measurement of the periodontal ligament space
Arm Type
Other
Arm Description
Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
Arm Title
Radiographic analysis of oro-facial manifestations
Arm Type
Other
Arm Description
Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
Intervention Type
Radiation
Intervention Name(s)
Cone Beam Computed Tomography (CBCT)
Primary Outcome Measure Information:
Title
Measurement of the periodontal ligament space width at mid-root level on Cone Beam Computed Tomography (CBCT) axial views
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
Radiographic analysis of oro-facial manifestations associated with systemic sclerosis using high-resolution volumetric Cone Beam Computed Tomography (CBCT) exploration
Time Frame
Baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Common inclusion criteria Males and females ≥ 18 years (18th birthday completed) Affiliation to a social security scheme Signed informed consent form prior to inclusion in the study More than 12 natural teeth suitable for evaluation Inclusion criteria for systemic sclerosis patients Systemic sclerosis Inclusion criteria for control Subjet that underwent or must undergo an upper and a lower jaw bone Cone Beam Computed Tomography examination (impacted teeth assessment, implant treatment planning) Exclusion Criteria: Common exclusion criteria Overt acute or chronic infection (HIV, viral hepatitis…) known at the time of the oral examination Progressive neoplasia or neoplasia diagnosed within 2 years prior to the study Ongoing antibiotic treatment or within 3 months before oral examination Individuals at risk of infective endocarditis Oral antiseptics within the week before oral examination (chlorhexidine mouthwashes…) Periodontal specialized treatments, root scaling/root planning or periodontal surgical treatment within the year before oral examination Ongoing medical treatment inducing a significant modification of the gingival state (anti-epileptic drugs…) Smoking (≥ 10 cigarettes per day) Pregnancy female subjects (positive urine pregnancy test) Lactating female subjects Impossibility to provide accurate informations (emergency situation, comprehension difficulties…) Exclusion criteria for systemic sclerosis patients Patient currently involved in an other clinical trial (drug) or in an exclusion period following participation in another clinical trial Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…) Progressive chronic illness other than systemic sclerosis (diabetes…) Immunosuppressive therapy during the last month Corticosteroid ≥10 mg/day during the last month Hematopoietic stem cell transplant recipient Another cause of skin sclerosis (radiotherapy on the oro-facial region…) Exclusion criteria for control Systemic chronic or evolutive illness at the time of the inclusion Progressive pathology involving the maxilla or the mandible at the time of the inclusion (tumor…) Ongoing treatment with corticsteroids or non-steroidal anti-inflammatory drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sophie JUNG, Dental surgeon
Organizational Affiliation
Les Hôpitaux Universitaires de Strasbourg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de parodontologie
City
Strasbourg
ZIP/Postal Code
67000
Country
France

12. IPD Sharing Statement

Learn more about this trial

Oral Manifestations of Systemic Sclerosis

We'll reach out to this number within 24 hrs